Aankondiging • Jun 03
Mochida Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026 Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 03, 2026 Reported Earnings • May 20
Full year 2026 earnings released: EPS: JP¥223 (vs JP¥160 in FY 2025) Full year 2026 results: EPS: JP¥223 (up from JP¥160 in FY 2025). Revenue: JP¥117.0b (up 11% from FY 2025). Net income: JP¥7.90b (up 39% from FY 2025). Profit margin: 6.8% (up from 5.4% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Board Change • May 20
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Outside Director Sanae Tanaka was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Aankondiging • May 15
Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026 Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026. Aankondiging • May 09
Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026 Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026 Aankondiging • Mar 30
Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 530,000 shares, representing 1.5% for ¥2,000 million. Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 530,000 shares, representing 1.5% of its total shares outstanding (excluding treasury shares), for a total of ¥2,000 million. The repurchase program is valid till December 18, 2026. As of February 28, 2026, the company had 35,449,727 shares outstanding (excluding treasury shares) and had 940,273 shares in treasury. Aankondiging • Nov 29
Mochida Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026 Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026 Aankondiging • Sep 23
Mochida Pharmaceutical Co., Ltd. (TSE:4534) agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH for ¥16.2 billion. Mochida Pharmaceutical Co., Ltd. (TSE:4534) agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH for ¥16.2 billion on September 19, 2025. On September 22, 2025, an agreement was signed by the parties. A cash consideration of ¥16.2 billion will be paid by Mochida Pharmaceutical Co., Ltd. In a related transaction, ITOCHU Corporation also agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH.
The expected completion of the transaction is October 1, 2025. Aankondiging • Sep 02
Mochida Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 04, 2025 Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 04, 2025 Aankondiging • Jun 27
Mochida Pharmaceutical Co., Ltd. Approves Changes to the Special Committee Members Mochida Pharmaceutical Co., Ltd. at its AGM held on June 27, 2025 approved changes of the Special Committee members under the Policy. Special Committee members after the changes as follows: Shigeaki Yoshikawa, Born in 1962; Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd.; Mar. 2015 Outside Director At Pilot Corporation May. 2015 Outside Director At Shochiku Co., Ltd. Mar. 2023; Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present) June 2023; Outside Director At Tv Asahi Holdings Corporation (To the Present); June 2025 Outside Director of the Company (To the Present). Yoshifumi Miyata; Born in 1952. Career Summary: Apr. 1978 Joined the Dai-Ichi Mutual Life Insurance Company; Apr. 2006 Executive Officer and General Manager of Financial Institution Relations Department At the Dai-Ichi Mutual Life Insurance Company; Apr. 2009 Managing Executive Officer of the Dai-Ichi Mutual Life Insurance Company Jun. 2010 Outside Audit & Supervisory Board Member of Tsugami Corporation; Jun. 2012 Representative Director and Vice-President of Trust & Custody Services Bank, Ltd.; Oct. 2018 Outside Director At Wellnest Communications Inc. (To the Present); Jun. 2021 Outside Audit & Supervisory Board Member of the Company (To the Present). Sanae Tanaka; Born in 1962. Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd; Mar. 2015 Outside Director At Pilot Corporation; May. 2015 Outside Director At Shochiku Co., Ltd.; Mar. 2023 Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present); Jun. 2023 Outside Director At Tv Asahi Holdings Corporation (To the Present) Jun. 2025 Outside Director of the Company (To the Present). Aankondiging • Jun 04
Mochida Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 01, 2025 Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 01, 2025 Aankondiging • Mar 04
Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025 Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025 Aankondiging • Nov 30
Mochida Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025 Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025 Reported Earnings • Nov 03
Second quarter 2025 earnings released: EPS: JP¥35.85 (vs JP¥32.03 in 2Q 2024) Second quarter 2025 results: EPS: JP¥35.85 (up from JP¥32.03 in 2Q 2024). Revenue: JP¥25.7b (up 3.9% from 2Q 2024). Net income: JP¥1.27b (up 11% from 2Q 2024). Profit margin: 4.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 65% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.1%). New Risk • Sep 17
New major risk - Revenue and earnings growth Earnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.7% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows. Buy Or Sell Opportunity • Aug 29
Now 21% undervalued Over the last 90 days, the stock has risen 16% to €20.00. The fair value is estimated to be €25.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 27%. Revenue is forecast to grow by 4.8% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Aankondiging • Aug 27
Mochida Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 01, 2024 Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 01, 2024 Reported Earnings • Aug 05
First quarter 2025 earnings released: EPS: JP¥43.84 (vs JP¥46.23 in 1Q 2024) First quarter 2025 results: EPS: JP¥43.84 (down from JP¥46.23 in 1Q 2024). Revenue: JP¥25.4b (up 2.7% from 1Q 2024). Net income: JP¥1.55b (down 7.9% from 1Q 2024). Profit margin: 6.1% (down from 6.8% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Aug 02
Now 22% undervalued Over the last 90 days, the stock has risen 2.6% to €19.50. The fair value is estimated to be €25.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 22%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Declared Dividend • Jul 11
Final dividend of JP¥40.00 announced Shareholders will receive a dividend of JP¥40.00. Ex-date: 27th September 2024 Payment date: 2nd December 2024 Dividend yield will be 219%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (144% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 60% to bring the payout ratio under control. EPS is expected to grow by 54% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Aankondiging • Jun 06
Mochida Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 02, 2024 Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 02, 2024 Reported Earnings • May 16
Full year 2024 earnings released: EPS: JP¥127 (vs JP¥179 in FY 2023) Full year 2024 results: EPS: JP¥127 (down from JP¥179 in FY 2023). Revenue: JP¥102.9b (flat on FY 2023). Net income: JP¥4.55b (down 32% from FY 2023). Profit margin: 4.4% (down from 6.4% in FY 2023). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Aankondiging • May 15
Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024 Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is on the higher end at 96% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.9%). In line with average of industry peers (2.4%). Aankondiging • Mar 02
Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024 Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024 Reported Earnings • Feb 06
Third quarter 2024 earnings released: EPS: JP¥45.16 (vs JP¥112 in 3Q 2023) Third quarter 2024 results: EPS: JP¥45.16 (down from JP¥112 in 3Q 2023). Revenue: JP¥28.7b (up 1.9% from 3Q 2023). Net income: JP¥1.61b (down 61% from 3Q 2023). Profit margin: 5.6% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 15% per year. Aankondiging • Dec 02
Mochida Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 05, 2024 Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 05, 2024 Reported Earnings • Nov 04
Second quarter 2024 earnings released: EPS: JP¥32.02 (vs JP¥20.52 in 2Q 2023) Second quarter 2024 results: EPS: JP¥32.02 (up from JP¥20.52 in 2Q 2023). Revenue: JP¥24.7b (down 3.1% from 2Q 2023). Net income: JP¥1.15b (up 50% from 2Q 2023). Profit margin: 4.7% (up from 3.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥40.00 per share at 2.4% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 01 December 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.5%). Aankondiging • Aug 30
Mochida Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 02, 2023 Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 02, 2023 Reported Earnings • Aug 09
First quarter 2024 earnings released: EPS: JP¥46.23 (vs JP¥83.98 in 1Q 2023) First quarter 2024 results: EPS: JP¥46.23 (down from JP¥83.98 in 1Q 2023). Revenue: JP¥24.7b (down 11% from 1Q 2023). Net income: JP¥1.69b (down 47% from 1Q 2023). Profit margin: 6.8% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Aankondiging • May 31
Mochida Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023 Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023 Reported Earnings • May 17
Full year 2023 earnings released: EPS: JP¥179 (vs JP¥277 in FY 2022) Full year 2023 results: EPS: JP¥179 (down from JP¥277 in FY 2022). Revenue: JP¥103.3b (down 6.3% from FY 2022). Net income: JP¥6.65b (down 37% from FY 2022). Profit margin: 6.4% (down from 9.6% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥40.00 per share at 2.4% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.8%). Reported Earnings • Feb 09
Third quarter 2023 earnings released: EPS: JP¥112 (vs JP¥138 in 3Q 2022) Third quarter 2023 results: EPS: JP¥112 (down from JP¥138 in 3Q 2022). Revenue: JP¥28.2b (down 8.5% from 3Q 2022). Net income: JP¥4.16b (down 21% from 3Q 2022). Profit margin: 15% (down from 17% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Aankondiging • Nov 27
Mochida Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 06, 2023 Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 06, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022) Second quarter 2023 results: EPS: JP¥20.52 (down from JP¥59.14 in 2Q 2022). Revenue: JP¥25.5b (down 4.3% from 2Q 2022). Net income: JP¥768.0m (down 66% from 2Q 2022). Profit margin: 3.0% (down from 8.5% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Tomoaki Sonoda was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 06
Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022) Second quarter 2023 results: EPS: JP¥20.52 (down from JP¥59.14 in 2Q 2022). Revenue: JP¥25.5b (down 4.3% from 2Q 2022). Net income: JP¥768.0m (down 66% from 2Q 2022). Profit margin: 3.0% (down from 8.5% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 01 December 2022. Payout ratio is a comfortable 31% and the cash payout ratio is 77%. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (2.9%). Aankondiging • Aug 27
Mochida Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 04, 2022 Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2023 results on Nov 04, 2022 Reported Earnings • Aug 02
First quarter 2023 earnings released: EPS: JP¥83.98 (vs JP¥69.33 in 1Q 2022) First quarter 2023 results: EPS: JP¥83.98 (up from JP¥69.33 in 1Q 2022). Revenue: JP¥27.7b (up 1.2% from 1Q 2022). Net income: JP¥3.16b (up 19% from 1Q 2022). Profit margin: 11% (up from 9.7% in 1Q 2022). Over the next year, revenue is forecast to stay flat compared to a 8.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Aankondiging • Aug 02
Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million. Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 1,190,000 shares, representing 3.17% of its total shares outstanding (excluding treasury shares), for a total of ¥3,500 million. The purpose of repurchase program is to flexibly invest capital in response to changes in the business environment, in addition to enhancing shareholder returns and improving capital efficiency. The repurchase program is valid till March 24, 2023. As of July 31, 2022, the company had 37,569,339 shares outstanding (excluding treasury shares) and had 2,590,661 shares in treasury. Aankondiging • May 29
Mochida Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022 Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Aug 01, 2022 Reported Earnings • May 16
Full year 2022 earnings released: EPS: JP¥277 (vs JP¥222 in FY 2021) Full year 2022 results: EPS: JP¥277 (up from JP¥222 in FY 2021). Revenue: JP¥110.2b (up 7.0% from FY 2021). Net income: JP¥10.6b (up 23% from FY 2021). Profit margin: 9.6% (up from 8.3% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to stay flat compared to a 6.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Aankondiging • May 15
Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022 Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 2 independent directors (8 non-independent directors). Outside Director Nana Otsuki was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Aankondiging • Apr 08
Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (2.6%). Reported Earnings • Feb 06
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: EPS: JP¥138 (up from JP¥77.56 in 3Q 2021). Revenue: JP¥30.8b (up 9.0% from 3Q 2021). Net income: JP¥5.26b (up 76% from 3Q 2021). Profit margin: 17% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.7%. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 06
Second quarter 2022 earnings released: EPS JP¥59.13 (vs JP¥52.74 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥26.6b (up 9.9% from 2Q 2021). Net income: JP¥2.26b (up 11% from 2Q 2021). Profit margin: 8.5% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.7%). Reported Earnings • Aug 03
First quarter 2022 earnings released: EPS JP¥69.33 (vs JP¥86.88 in 1Q 2021) The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2022 results: Revenue: JP¥27.4b (flat on 1Q 2021). Net income: JP¥2.65b (down 21% from 1Q 2021). Profit margin: 9.7% (down from 12% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • May 17
Full year 2021 earnings released: EPS JP¥222 (vs JP¥118 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥103.0b (up 1.2% from FY 2020). Net income: JP¥8.59b (up 87% from FY 2020). Profit margin: 8.3% (up from 4.5% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Mar 24
Upcoming dividend of JP¥40.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 29 June 2021. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.0%). Is New 90 Day High Low • Feb 16
New 90-day high: €33.80 The company is up 2.0% from its price of €33.00 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. Reported Earnings • Feb 07
Third quarter 2021 earnings released: EPS JP¥77.56 (vs JP¥45.66 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥28.3b (up 2.4% from 3Q 2020). Net income: JP¥3.00b (up 68% from 3Q 2020). Profit margin: 11% (up from 6.5% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 07
Revenue beats expectations Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 1.4%, compared to a 2.3% growth forecast for the Pharmaceuticals industry in Germany. Aankondiging • Jan 12
Mochida Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 05, 2021 Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2021 results on Feb 05, 2021 Is New 90 Day High Low • Dec 24
New 90-day low: €29.80 The company is down 9.0% from its price of €32.80 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Analyst Estimate Surprise Post Earnings • Nov 15
Revenue misses expectations Revenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 1.6%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Nov 15
Second quarter 2021 earnings released: EPS JP¥52.74 The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: JP¥24.2b (down 3.1% from 2Q 2020). Net income: JP¥2.04b (up 59% from 2Q 2020). Profit margin: 8.4% (up from 5.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Nov 05
Revenue misses expectations Revenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 3.0%, compared to a 2.6% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Nov 05
Second quarter 2021 earnings released: EPS JP¥52.74 The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: JP¥24.2b (down 3.1% from 2Q 2020). Net income: JP¥2.04b (up 59% from 2Q 2020). Profit margin: 8.4% (up from 5.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Sep 28
New 90-day high: €34.80 The company is up 7.0% from its price of €32.60 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. 
